Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
Vascular endothelial growth factor A (VEGF-A) and vascular endothelial growth factor receptor 2 (VEGFR2) are the key factors mediating neo-vascularization. They are often coexpressed in breast cancer. Sex steroids may stimulate angiogenesis via the estrogen receptor (ER) pathway. We investigated to...
Հիմնական հեղինակներ: | Mele, T, Generali, D, Fox, S, Brizzi, M, Bersiga, A, Milani, M, Allevi, G, Bonardi, S, Aguggini, S, Volante, M, Dogliotti, L, Bottini, A, Harris, A, Berruti, A |
---|---|
Ձևաչափ: | Journal article |
Լեզու: | English |
Հրապարակվել է: |
2010
|
Նմանատիպ նյութեր
-
Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients
: Mele, T, և այլն
Հրապարակվել է: (2010) -
The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
: Fox, S, և այլն
Հրապարակվել է: (2011) -
The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
: Fox, S, և այլն
Հրապարակվել է: (2011) -
Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
: Generali, D, և այլն
Հրապարակվել է: (2009) -
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
: Generali, D, և այլն
Հրապարակվել է: (2009)